Skip to main content
Longeveron Inc. logo

Longeveron Inc. — Investor Relations & Filings

Ticker · LGVN ISIN · US54303L2034 US Manufacturing
Open in API
Filings indexed 463 across all filing types
Latest filing 2026-06-05 Board/Management Inform…
Country US United States of America
Listing US LGVN

About Longeveron Inc.

https://www.longeveron.com/

Longeveron Inc. is a clinical-stage biotechnology company that develops cellular therapies for aging-related and life-threatening conditions. The company's lead investigational product, laromestrocel (Lomecel-B™), is a cell-based therapy designed to repair, regenerate, and restore damaged tissue. Longeveron's clinical development is focused on several key indications, including Hypoplastic Left Heart Syndrome (HLHS), a rare congenital heart defect in infants for which it has an orphan drug designation. Other primary clinical programs target Alzheimer's disease and Aging Frailty. For its Alzheimer's program, the U.S. FDA has granted laromestrocel both Regenerative Medicine Advanced Therapy (RMAT) and Fast Track designations. The company's research aims to improve healthspan by addressing unmet medical needs.

Recent filings

Filing Released Lang Actions
CURRENT REPORT
Board/Management Information Classification · 95% confidence The document is a Form 8-K Current Report filed under Item 5.02, detailing the departure of the Chief Financial Officer and appointment plans for her successor. This constitutes an announcement of changes in senior management. According to the filing definitions, this falls under Board/Management Information (Code: MANG).
2026-06-05 English
ARS
Annual Report FY 2025
2026-05-20 English
DEFINITIVE ADDITIONAL MATERIALS
Proxy Solicitation & Information Statement
2026-05-20 English
PROXY STATEMENT
Proxy Solicitation & Information Statement
2026-05-20 English
10-Q - Longeveron Inc. (0001721484) (Filer)
Interim / Quarterly Report Q1 2026
2026-05-13 English
424B3 - Longeveron Inc. (0001721484) (Filer)
Capital/Financing Update Classification · 95% confidence The document is a prospectus filed pursuant to Rule 424(b)(3) related to the resale of shares by selling stockholders. It details the offering of Class A common stock, registration rights, selling stockholders, and terms of the resale. The document is not a financial report, earnings release, or management discussion. It is a formal offering document related to capital markets and securities registration. This fits the definition of a Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes. The document is lengthy (15,000 characters) and contains detailed offering information, not just an announcement or notice, so it is not an RPA or RNS. Therefore, the correct classification is CAP with high confidence.
2026-04-17 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.